In a report released today, Steven Lichtman from Oppenheimer assigned a Hold rating to Insulet (PODD), with a price target of $235.00. The company’s shares closed last Wednesday at $231.43.
According to TipRanks.com, Lichtman is a 4-star analyst with an average return of 4.3% and a 50.1% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Helius Medical Technologies, Merit Medical Systems, and Integra Lifesciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Insulet with a $240.85 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $255.39 and a one-year low of $121.00. Currently, Insulet has an average volume of 395.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Insulet Corp. is a medical device company. The firm engages in the development, manufacture and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.
